Contrive Datum Insights has published "Pen Needles Market Size, Share & Industry Analysis, By Product type (Standard pen needles, Safety pen needles), Length (4mm, 5mm, 6mm, 8mm, 10mm, 12mm), Therapy (Insulin therapy, Glucagon-like Peptide-1 (GLP-1) therapy, Growth hormone therapy, Other therapies), Mode of purchase (Retail, Non-Retail), End user (Homecare Settings, Hospitals & Clinics, Other End Users), and Regional Forecast, 2026-2034". The study sizes the global pen needles market at USD 4.4 billion in 2025 and projects growth from USD 4.88 billion in 2026 to USD 10.02 billion by 2034, a compound annual growth rate of 9.41% across the forecast period.
Pen needles are single-use, disposable needle attachments designed to fit reusable and prefilled injector pens used to self-administer subcutaneous medication, most commonly insulin and other chronic-condition injectables. They come in standard and safety-engineered designs, with needle lengths and gauges suited to different patient body types and therapy requirements. Buyers span individual patients purchasing through retail and online pharmacies, hospitals and clinics procuring for in-facility administration, and distributors supplying long-term care and other institutional settings.
Rising GLP-1 and insulin therapy prescribing expanding the self-injecting patient base
Rising GLP-1 and insulin therapy prescribing expanding the self-injecting patient base is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 9.41% a year, the product type lines exposed to it move fastest: Safety pen needles compounds at 12.68%, taking its share of revenue from 32.05% to 42.02% and its value from USD 1.41 billion to USD 4.21 billion.
On the upside, the study's bull case assumes bull case assumes faster GLP-1 prescribing growth and quicker adoption of safety pen needles across both developed and emerging markets, lifting volumes above the base forecast, which would take 2034 revenue to USD 11.42 billion rather than the USD 10.02 billion base case.
However, bear case assumes slower GLP-1 volume growth, tighter payer pricing pressure, and delayed safety-needle regulatory adoption, holding volumes below the base forecast, which would hold 2034 revenue to USD 8.62 billion. Standard pen needles, which carries 67.95% of 2025 revenue, already grows at only 7.49% against the market's 9.41%, so the largest part of the base is also its slowest.
Key Players Compete on Standard pen needles Volume and Safety pen needles Growth
Competition in the global pen needles market runs along the product type axis rather than the regional one. Standard pen needles holds 67.95% of 2025 revenue at USD 2.99 billion and remains the largest line through 2034 at 57.98%, making it the position hardest for a challenger to take. Safety pen needles, growing at 12.68%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 4.4 billion.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Product type | Standard pen needles | 67.95% · USD 2.99 billion | — |
| Length | 4mm | 38.18% · USD 1.68 billion | — |
| Therapy | Insulin therapy | 57.95% · USD 2.55 billion | Glucagon-like Peptide-1 (GLP-1) therapy 15.28% |
| Mode of purchase | Retail | 64.09% · USD 2.82 billion | — |
| End user | Homecare Settings | 72.05% · USD 3.17 billion | — |
- Based on regional analysis, North America led the global pen needles market in 2025 with 37.95% of global revenue at USD 1.67 billion, reaching USD 3.61 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 24.09% in 2025 to 27.05% in 2034, with revenue growing from USD 1.06 billion to USD 2.71 billion.
- Middle East and Africa remains the smallest region throughout, at 5% of 2025 revenue and 5.49% by 2034.
- Safety pen needles is projected to grow at 12.68% over the forecast period, the fastest of any product type line.
- The United States is the largest single country market at USD 1.47 billion in 2025, 33.41% of global revenue.
The report segments the market across five axes; by product type, and by length, therapy, mode of purchase and end user; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 8.62 billion and USD 11.42 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.